Skip to Content

Vascular Surgery Trials

ANCHOR - Aneurysm Treatment using the HeliFX Aortic Securement System Global Registry
Aims: Endografts are often employed in the treatment of Abdominal Aortic Aneurysms.  The Aptus HeliFX Aortic Securement System allows the surgeon to use EndoAnchors, similar to small screws, to secure the endograft to the wall of the aorta, providing additional fixation and sealing of the endograft in place.  The system can be used in either:          

  • patients who already have an endograft (previously placed) that the surgeon thinks will benefit from additional securing or,
  • patients who are undergoing placement of an initial endoqraft repair, particularly those whose anatomy may make securing the graft without the use of EndoAnchors difficult (the surgeon believes the endograft may be at risk of not “fixing” to the wall of the aorta, or not sealing well).

This Global Registry will allow for the collection of clinical data on patients who have had the EndoAnchors placed in their endograft and to expand the knowledge of how well the system is working over a broad spectrum of geographies and a variety of practicing clinicians.
Diagnosis: Abdominal aortic aneurysm (AA); Endoleak
Principal Investigator: Omar Morcos, MD
IRB Approval Number: EH12-461
Sponsor: Medtronic, Inc.
Contact: Interested patients may contact Karen Hynes at 224.251.4820,
Open to Enrollment: Yes 

Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: Management of Patients Who Are Receiving a Novel Oral Anticoagulant (Dabigatran, Rivaroxaban or Apixaban) and Require an Elective Surgery or Medical Procedure: A Prospective Cohort Study

Aims: Patients who are taking today’s newer blood thinners and need to have a surgical procedure, need only to stop these medications for 24-48 hours, unlike long-used anti-platelet medications such as warfarin or aspirin. This study is observational (no treatment or study visits), involving follow-up phone calls once a week for 4 weeks.

Diagnosis: Patients currently taking Xeralto, Eliquis or Pradaxa
Principal Investigator: Alfonso Tafur, MD
IRB Approval Number: EH15-349
Sponsor: McMaster University Medical Center (grant funding from the Canadian Institutes for Health Research and the Heart and Stroke Foundation)
Contact: Interest patients may contact Linda Pierchala, RN at 847.570.1997 or
Open to Enrollment: Yes

RIETE: Computerized Registry of Patients with Venous Thromboembolism
Aims: The RIETE Registry is a multidisciplinary project aimed at providing information on the Internet that helps physicians  improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (pregnant women, elderly patients, disseminated cancer, severe renal insufficiency, patients with contraindications to anticoagulation therapy pr extreme body weight), with the purpose of decreasing mortality, frequency of thromboembolic recurrences, as well as bleeding complications and arterial events. RIETE also aims to create predictive scores that help physicians to better identify patients with high risk of developing some of these complications.

Diagnosis: Acute deep vein thrombosis (DVT), pulmonary embolism (PE) and/or superficial venous thrombosis (SVT)
Principal Investigator: Alfonso Tafur, MD and Lauren Cote, RN
IRB Approval Number: 
Sponsor: Manuel Monreal, Foundation for the study of VTE diseases
Contact: Interested patients may contact Lauren Cote, RN at 847.570.2428 or
Open to Enrollment: Yes 

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS)
Aims: The purpose of this study is to compare the benefits, harms, and burdens of two different approaches to anticoagulation therapy in patients with cancer. Although DOACs are FDA-approved, they have not been extensively studied in patients with cancer.

Diagnosis: Cancer with a blood clot
Principal Investigator: Alfonso Tafur, MD
IRB Approval Number: EH17-042
Sponsor: Alliance Foundation Trial
Contact: Interested patients may contact Elita Fine at 847.570-2698
Open to Enrollment: Yes